Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20–24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.
Citations
Citations to this article as recorded by
Computational insights into potential marine natural products as selective inhibitors of Mycobacterium tuberculosis InhA: A structure-based virtual screening study Manikandan Jayaraman, Vijayakumar Gosu, Rajalakshmi Kumar, Jeyakanthan Jeyaraman Computational Biology and Chemistry.2024; 108: 107991. CrossRef
Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors** Waseem Ali, Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, Sonam Grover Molecular Informatics.2024;[Epub] CrossRef
A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT) Ashwin Karnan, Ulhas Jadhav, Babaji Ghewade, Anjana Ledwani, Poorna Shivashankar Cureus.2024;[Epub] CrossRef
Design, synthesis and biological evaluation of novel pyrido-[2,3-d]-pyrimidin-2-amine analogues as antimycobacterial agents Boddupalli Venkata Siva Kumar, Yogesh Mahadu Khetmalis, Kosana Sai Chaitanya, Ala Chandu, Gauri Shetye, Rui Ma, Sankaranarayanan Murugesan, Scott G. Franzblau, Kondapalli Venkata Gowri Chandra Sekhar Journal of Molecular Structure.2024; 1303: 137600. CrossRef
Direct TAMRA-dUTP labeling of M. tuberculosis genes using loop-mediated isothermal amplification (LAMP) Basma Altattan, Jasmin Ullrich, Emily Mattig, Aline Poppe, Renata Martins, Frank F. Bier Scientific Reports.2024;[Epub] CrossRef
Antimicrobial peptides as new-generation antibiotics against Mycobacterium Parisa Eslami, Adnan Khosravi Journal of Preventive, Diagnostic and Treatment Strategies in Medicine.2024; 3(1): 6. CrossRef
A Case of Multidrug-Resistant Tuberculosis in an Active Duty Military Health Care Worker Amanda E Saunders, Kevin M Shanahan, John W Downs Military Medicine.2024;[Epub] CrossRef
Factors Associated with Non-Adherence to Treatment Among Migrants with MDR-TB in Wuhan, China: A Cross-Sectional Study Kunhe Lin, Li Xiang Risk Management and Healthcare Policy.2024; Volume 17: 727. CrossRef
Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis Himanshu Paliwal, Titpawan Nakpheng, Pijush Kumar Paul, K. Prem Ananth, Teerapol Srichana International Journal of Pharmaceutics.2024; 655: 124031. CrossRef
Drug Targets, Current and Future Therapeutics for the Treatment of
Multi Drug Resistant Tuberculosis with their Clinical Applications: A
Critical Review Deepshikha Singh, Vikram Singh, Subhankar P. Mandal, Karen Dsouza, B.R. Prashantha Kumar, Sheshagiri R. Dixit Current Drug Therapy.2024; 19(3): 317. CrossRef
Synthesis and Structure–Activity Relationship of 2,6-Disubstituted Thiosemicarbazone Derivatives of Pyridine as Potential Antituberculosis Agents Dagmara Ziembicka, Katarzyna Gobis, Małgorzata Szczesio, Andrzej Olczak, Ewa Augustynowicz-Kopeć, Agnieszka Głogowska, Izabela Korona-Głowniak, Krzysztof Bojanowski Materials.2023; 16(1): 448. CrossRef
Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now Kona Chowdhury, Rahnuma Ahmad, Susmita Sinha, Siddhartha Dutta, Mainul Haque Cureus.2023;[Epub] CrossRef
Anxiety and depression level of patients with multidrug-resistant tuberculosis (MDR-TB) in two hospitals in Banten province, Indonesia Tirta Darmawan Susanto, Allen Widysanto, Darien Alfa Cipta, Arron Tanara, Ghivarell Rizkie Wirawan, Adeline Bercadina Kosim, Christabella Maria Djoni, Ervinna Tantri, Chandni Kumar, Chelsie Angelius Dialogues in Health.2023; 2: 100115. CrossRef
Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Wiwik Kurnia Ilahi, Amelia Tantri Anggraeni Antibiotics.2023; 12(3): 598. CrossRef
Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics Srestha Mukherjee, Summaya Perveen, Anjali Negi, Rashmi Sharma Tuberculosis.2023; 140: 102340. CrossRef
Assessment of the Diagnostic Utility of GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/RIF) Assay in the Suspected Cases of Tuberculous Meningitis Sakshi Patel, Malti Dadheech, Anand K Maurya, Jitendra Singh, Shashank Purwar, Nirendra Rai, Radha Sarawagi, Ankur Joshi, Sagar Khadanga Cureus.2023;[Epub] CrossRef
Tandem LC-MS Identification of Antitubercular Compounds in Zones of Growth Inhibition Produced by South African Filamentous Actinobacteria Daniel J. Watson, Lubbe Wiesner, Tlhalefo Matimela, Denzil Beukes, Paul R. Meyers Molecules.2023; 28(11): 4276. CrossRef
Drug-Resistant Tuberculosis Stigma Among HealthCare Workers Toward the Development of a Stigma-Reduction Strategy: A Scoping Review Lolita Liboon Aranas, Khorshed Alam, Prajwal Gyawali, Rashidul Mahumud Alam INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2023;[Epub] CrossRef
Quality Mindset: The Missing Ingredient in Tuberculosis Care and Control in Togo Kossivi Agbélénko Afanvi, Mohammed Fall Dogo, Koffi Atsu Aziagbé, Komi Séraphin Adjoh, Koumavi Kristoli Didier Ekouévi European Journal of Theoretical and Applied Sciences.2023; 1(4): 36. CrossRef
Machine Learning of the Whole Genome Sequence of Mycobacterium tuberculosis: A Scoping PRISMA-Based Review Ricardo Perea-Jacobo, Guillermo René Paredes-Gutiérrez, Miguel Ángel Guerrero-Chevannier, Dora-Luz Flores, Raquel Muñiz-Salazar Microorganisms.2023; 11(8): 1872. CrossRef
Cotreatment With Clofazimine and Rapamycin Eliminates Drug-Resistant Tuberculosis by Inducing Polyfunctional Central Memory T-Cell Responses Dhiraj Kumar Singh, Ashima Bhaskar, Isha Pahuja, Aishwarya Shaji, Barnani Moitra, Yufang Shi, Ved Prakash Dwivedi, Gobardhan Das The Journal of Infectious Diseases.2023; 228(9): 1166. CrossRef
Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil Fernanda Bruzadelli Paulino da Costa, Thaís Zamboni Berra, Jaqueline Garcia de Almeida Ballestero, Patricia Bartholomay Oliveira, Daniele Maria Pelissari, Yan Mathias Alves, Antônio Carlos Vieira Ramos, Juliana Queiroz Rocha de Paiva, Titilade Kehinde Aya Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100388. CrossRef
Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis Giuseppe Mancuso, Angelina Midiri, Silvia De Gaetano, Elena Ponzo, Carmelo Biondo Microorganisms.2023; 11(9): 2277. CrossRef
Drug-resistant Monoarticular Wrist Joint Tuberculosis in Renal Transplant Recipient with Literature Review Jasmine Sethi, Vignesh Subramani, Rajender Kumar, Shivakumar Patil, Ashish Sharma Indian Journal of Transplantation.2023; 17(3): 371. CrossRef
Predictive capabilities of baseline radiological findings for early and late disease outcomes within sensitive and multi-drug resistant tuberculosis cases Gabriel Rosenfeld, Andrei Gabrielian, Darrell Hurt, Alex Rosenthal European Journal of Radiology Open.2023; 11: 100518. CrossRef
Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies Mahesh Kumar, Tarun Virmani, Girish Kumar, Rohitas Deshmukh, Ashwani Sharma, Sofia Duarte, Pedro Brandão, Pedro Fonte Pharmaceuticals.2023; 16(10): 1360. CrossRef
A systematic review and meta-analysis on the correlation between HIV infection and multidrug-resistance tuberculosis Yulong Song, Qian Jin, Jihai Qiu, Dan Ye Heliyon.2023; 9(11): e21956. CrossRef
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults Sofiati Dian, Ahmad Rizal Ganiem, Lindsey HM te Brake, Arjan van Laarhoven CNS Drugs.2023; 37(11): 957. CrossRef
Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis Temesgen Yihunie Akalu, Archie C. A. Clements, Haileab Fekadu Wolde, Kefyalew Addis Alene Scientific Reports.2023;[Epub] CrossRef
Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review Deepak Vishwakarma, Abhay Gaidhane, Sweta Sahu, Ashwini S Rathod Cureus.2023;[Epub] CrossRef
Multidrug-resistant Tuberculosis and its Implication with COVID-19 Jasmine Arya, Sweety Dahiya, Anil Kumar Chhillar Coronaviruses.2023;[Epub] CrossRef
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance Summaya Perveen, Diksha Kumari, Kuljit Singh, Rashmi Sharma European Journal of Medicinal Chemistry.2022; 229: 114066. CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Case Report and Review of the Literature Ikhwan Rinaldi, Abdul Muthalib, Djaja Gosal, Teguh Wijayadi, Barlian Sutedja, Tjondro Setiawan, Andika Gunawan, Nelly Susanto, Lingga Magdalena, Diah Rini Handjari, Fetisari Kurniawan, Aisyah Rifani, Kevin Winston International Medical Case Reports Journal.2022; Volume 15: 169. CrossRef
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough? Lehlogonolo N. F. Maphalle, Bozena B. Michniak-Kohn, Modupe O. Ogunrombi, Oluwatoyin A. Adeleke Children.2022; 9(8): 1120. CrossRef
Various approaches to improving adherence of patients with tuberculosis. Prospects for the use of additive technologies in TB practice A. G. Naumov, A. S. Shprykov PULMONOLOGIYA.2022; 34(1): 80. CrossRef
Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review Gabriel S. Oliveira, Raquel P. Costa, Paula Gomes, Maria Salomé Gomes, Tânia Silva, Cátia Teixeira Pharmaceuticals.2021; 14(4): 323. CrossRef
Treatment of Human Babesiosis: Then and Now Isaline Renard, Choukri Ben Mamoun Pathogens.2021; 10(9): 1120. CrossRef
Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand Ei Phoo Thwe, Wises Namwat, Porntip Pinlaor, Kulrattana Rueangsak, Arunnee Sangka World Journal of Microbiology and Biotechnology.2021;[Epub] CrossRef
On the Mechanism of Development of Autoimmune Diseases Following Exposure to Inactivated Mycobacterium tuberculosis SV Skupnevskiy, GM Trukhina, EG Pukhaeva, AK Badtiev, FK Rurua, FE Batagova, ZhG Farnieva ЗДОРОВЬЕ НАСЕЛЕНИЯ И СРЕДА ОБИТАНИЯ - ЗНиСО / PUBLIC HEALTH AND LIFE ENVIRONMENT.2021; : 76. CrossRef
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment Suman Saurabh, Pankaj Bhardwaj Journal of Family Medicine and Primary Care.2021; 10(12): 4607. CrossRef
Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis Ionela-Alina Grosu-Creangă, Antigona Carmen Trofor, Radu Adrian Crișan-Dabija, Daniela Robu-Popa, Cristina Mihaela Ghiciuc, Elena Cătălina Lupușoru Pneumologia.2021; 70(3): 117. CrossRef
Advances in the science and treatment of respiratory diseases Jin Hong Chung Yeungnam University Journal of Medicine.2020; 37(4): 251. CrossRef
Adrenocorticotropic hormone (ACTH)-producing pheochromocytoma has been rarely reported, whereas only a few cases of Cushing syndrome accompanied by opportunistic infections have been reported. We experienced a patient with pheochromocytoma with ectopic Cushing syndrome complicated by invasive aspergillosis. A 35-year-old woman presented with typical Cushingoid features. Her basal plasma cortisol, ACTH, and 24-hour urine free cortisol levels were significantly high, and 24-hour urine metanephrine and catecholamine levels were slightly elevated. The endogeneous cortisol secretion was not suppressed by either low- or high-dose dexamethasone. Abdominal computed tomography (CT) revealed a heterogeneous enhancing mass measuring approximately 2.5 cm in size in the left adrenal gland. No definitive mass lesion was observed on sellar magnetic resonance imaging. On fluorine-18 fluorodeoxyglucose positron emission tomography/CT, a hypermetabolic nodule was observed in the left upper lung. Thus, we performed a percutaneous needle biopsy, which revealed inflammation, not malignancy. Thereafter, we performed a laparoscopic left adrenalectomy, and its pathologic finding was a pheochromocytoma with positive immunohistostaining for ACTH. After surgery, the biochemistry was normalized, but the clinical course was fatal despite intensive care because of the invasive aspergillosis that included the lungs, retina, and central nervous system.
Citations
Citations to this article as recorded by
Ectopic ACTH- and/or CRH-Producing Pheochromocytomas Patrick F Elliott, Thomas Berhane, Oskar Ragnarsson, Henrik Falhammar The Journal of Clinical Endocrinology & Metabolism.2021; 106(2): 598. CrossRef
Ectopic adrenocorticotrophic hormone syndrome (EAS) with phaeochromocytoma: a challenging endocrine case with a happy ending Sharifah Faradila Wan Muhamad Hatta, Leoni Lekkakou, Ananth Viswananth, Harit Buch BMJ Case Reports.2019; 12(8): e230636. CrossRef
Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature Jenan N Gabi, Maali M Milhem, Yara E Tovar, Emhemmid S Karem, Alaa Y Gabi, Rodhan A Khthir Journal of the Endocrine Society.2018; 2(7): 621. CrossRef
Churg-Strauss syndrome (CSS) is a necrotizing vasculitis with extra-, peri-vascular eosinophilic infiltration. Chronic symmetric polyarthritis with the presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody are the mainstay of rheumatoid arthritis (RA) diagnosis. Mononeuritis multiplex is a peripheral neuropathy involving more than 2 separate nerve areas. A 62-year-old male patient was referred for left foot drop and polyarthritis of both hands and feet for 4 months. During evaluation, mononeuritis multiplex was detected on nerve conduction study and electromyography tests: vasculitis with neutrophil, eosinophil, and lymphocyte infiltration on peroneal nerve biopsy. A positive response to methacholin and bronchodilator was observed on the pulmonary function test. Radiologic tests showed peri-articular soft tissue swelling and osteopenia on both hand and foot. Marked peripheral eosinophilia, high RF, and positive perinuclear anti-neutrophil cytoplasmic antibody were detected on blood tests. Here, we report on a patient with overlap syndrome of CSS and RA with review of the relevant literature, from which a few references to overlap syndrome of CSS and RA were available.
The widely used polyethylene glycol (PEG)-based solutions have been proven effective for bowel preparation when 4 L of the solution is administered before colonoscopy. However, large volumes of the solutions are generally poorly tolerated. A new PEG-based solution consisting of 2 L of PEG and a high dose of ascorbic acid has recently become available. Electrolyte abnormalities caused by PEG-based solutions have rarely been reported. We report on a case of acute severe hyponatremia with associated generalized tonic-clonic seizures after bowel preparation with a low-volume PEG plus ascorbic acid solution in a 74-year-old woman with no history of seizures. She took a beta blocker, an angiotensin-converting enzyme inhibitor, and glimepiride for hypertension and diabetes mellitus. She showed general weakness, nausea, agitation, muscle cramping, and seizures after ingestion of the PEG plus ascorbic acid solution. Her serum sodium level was 112 mEq/L. Her symptoms improved after intravenous administration of hypertonic saline. Physicians should pay attention to screening for electrolytes and development of neurological symptoms during bowel preparation.